Nuclera Secures US$75m to Advance Protein Discovery System
Biotech firm Nuclera raises $75M to expand its cutting-edge protein discovery system, speeding up breakthroughs in labs worldwide.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1116 entries already.
Entries by Thomas Gabrielczyk
Purespring bags £80m to transform kidney disease treatment
/in News/by Thomas GabrielczykPurespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this funding also drew support from Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.
WHO: One billion US$ for global health
/in News/by Thomas GabrielczykA total of US$1bn was pledged to the WHO at this year’s World Health Summit in Berlin for the fight against Mpox, Marburg virus and the consequences of climate change.
Swiss Ikerian AG partner with Sanoptis Inc to market AI-image analysis
/in News/by Thomas GabrielczykSwiss Ikerian AG’s US-subsidiary, RetinAI U.S. Inc. has announced the first close of an CHF6.73m Series B financing with new and existing investors to advance its AI-based image analysis platform alongside a strategic partnership.
Antibody developer Yumab partners with Japanese AI specialist Molcure
/in News/by Thomas GabrielczykGerman antibody specialist YUMAB GmbH has inked a collaboration agreement with Japanese MOLCURE Inc aimed at using the company’s zero-shot AI technology for antibody discovery.
Forbion raises more than €2bn for two new funds
/in News/by Thomas GabrielczykDutch Forbion has announced its largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2bn and Forbion Ventures Fund VII raising €890m.
Lundbeck to take over Longboard Pharma in US$2.6bn transaction
/in News/by Thomas GabrielczykLundbeck A/S is set to take over all shares of neurology specialist Longboard Pharmaceuticals Inc worth US$2.6bn to strengthen its pipeline with the Phase III 5-hydroxythyprytamaine 2C receptor super-agonist bexicaserine to treat 11 rare neurological conditions.
Sphingotec licenses kidney function test
/in News/by Thomas GabrielczykGerman diagnostics company Sphingotec GmbH has licensed its real-time kidney function test to US diagnostics giant Beckman Coulter allowing it to expand its business to the US as announced earlier this month.
AviadoBio Ltd inks US$2.2bn gene therapy deal with Astellas Pharma Inc
/in News/by Thomas GabrielczykAviadoBio Ltd has cashed in €30m upfront and €20m as an equity investment from Astellas Pharma Inc for signing a licence option agreement for its Phase I/II gene therapy programme AVR-01.
Vicore secures funding to accelerate drug development
/in News/by Thomas GabrielczykSwedish clinical-stage pharmaceutical company Vicore Pharma has secured SEK100m, supported by existing and new investors. The injection of capital will allow the company to scale the clinical development of its portfolio of therapies in respiratory and fibrotic diseases.